The role of the mLDL-induced activation of the complement system classical pathway and C3 expression stimulation in atherosclerosis


Cite item

Full Text

Abstract

The role of modified low density lipoprotein in the activation of the classical pathway of the complement system and increasing expression C3 gene in human macrophages is described, role of these processes on the progression of atherosclerotic vascular lesions is considering.

About the authors

O M Drapkina

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

д.м.н., член-корр. РАН, первый заместитель директора по научной и лечебной работе, проф. каф. факультетской терапии Первого МГМУ им. И.М. Сеченова Moscow, Russia

B B Gegenava

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: gegenava.badri@gmail.com
врач-терапевт ЛДО №4 УКБ №2 Первого МГМУ им. И.М. Сеченова, аспирант кафедры пропедевтики внутренних болезней лечебного факультета Первого МГМУ им. И.М. Сеченова Moscow, Russia

V V Fomin

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

д.м.н., проф., член-корр. РАН, проректор Первого МГМУ им. И.М. Сеченова, зав. каф. факультетской терапии Первого МГМУ им. И.М. Сеченова Moscow, Russia

References

  1. Драпкина О.М., Гегенава Б.Б. Фиброз миокарда у больных сахарным диабетом. Эффективная фармакотерапия в кардиологии. 2013;9(1):62-5.
  2. Драпкина О.М., Гегенава Б.Б. Cтатины и углеводный обмен. Эффективная фармакотерапия. Эндокринология. 2015;(32):24-31
  3. Драпкина О.М., Гегенава Б.Б. Диабет и сердце - поражение миокарда при диабетической кардиомиопатии. Эндокринология: новости, мнения, обучение. 2015;(3):84-92
  4. Ricklin D, Hajishengallis G, Yang K, Lambris J.D. Complement: A key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785-97. doi: 10.1038/ni.1923
  5. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med. 1999;340:115-26. doi: 10.1056/NEJM199901143400207
  6. Getz G.S. Thematic review series. The immune system and atherogenesis. Immune function in atherogenesis. J Lipid Res. 2005;46:1-10. doi: 10.1194/jlr.R400013-JLR200
  7. Yasojima K, Schwab C, Mc Geer E.G, Mc Geer P.L. Complement components, but not complement inhibitors, are up - regulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1214-9. doi: 10.1161/hq0701.092160
  8. Hansson G.K, Holm J, Kral J.G. Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. Acta Pathol Microbiol Immunol Scand. 1984;A92:429-35. doi: 10.1111/j.1699-0463.1984.tb04424.x
  9. Schmiedt W, Kinscherf R, Deigner H.P, Kamencic H, Nauen O, Kilo J, Oelert H, Metz J, Bhakdi S. Complement C6 deficiency protects against diet - induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998;18:1790-5. doi: 10.1161/01.ATV.18.11.1790
  10. Patel S, Thelander E.M, Hernandez M, Montenegro J, Hassing H, Burton C, Mundt S, Hermanowski-Vosatka A, Wright S.D, Chao Y.S, Detmers P.A. ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun. 2001;286:164-70. doi: 10.1006/bbrc.2001.5276
  11. Buono C, Come C.E, Witztum J.L, Maguire G.F, Connelly P.W, Carroll M, Lichtman A.H. Influence of C3 deficiency on atherosclerosis. Circulation. 2002;105:3025-31. doi: 10.1161/01.CIR.0000019584. 04929.83
  12. Persson L, Borén J, Robertson A.K, Wallenius V, Hansson G.K, Pekna M. Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol. 2004;24:1062-7. doi: 10.1161/01.ATV.0000127302.24266.40
  13. Onat A, Can G, Rezvani R, Cianflone K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta. 2011;412:1171-9. doi: 10.1016/j.cca.2011.03.005
  14. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Drago G, Martignani C, Pacilli P, Boni P, Puddu P. Relationship of serum C3 to fasting insulin, risk factors, and previous ischaemic events in middle - aged men. Eur Heart J. 2000;21:1081-90. doi: 10.1053/euhj.1999.2013
  15. Ajjan R, Grant P.J, Futers T.S, Brown J.M, Cymbalista C.M, Boothby M, Carter A.M. Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb Haemost. 2005;94:1048-53. doi: 10.1160/TH05-06-0384
  16. Speidl W.S, Kastl S.P, Huber K, Wojta J. Complement in atherosclerosis: friend or foe? J Thromb Haemost. 2011;9:428-40. doi: 10.1111/j. 1538-7836.2010.04172.x
  17. Walport M.J. Complement. First of two parts. N Engl J Med. 2001;344:1058-66. doi: 10.1056/NEJM200104053441406
  18. Janeway C.A. Jr, Travers P, Walport M, Shlomchik M. Immunobiology: The Immune System in Health and Disease. 6th ed. New York: Garland Publishing; 2005.
  19. Volanakis J.E, Frank M.M. The Human Complement System in Health and Disease. New York: Marcel Dekker Inc.; 1998.
  20. Walport M.J. Complement. Second of two parts. N Engl J Med. 2001;344:1140-4. doi: 10.1056/NEJM200104123441506
  21. Dunkelberger J.R, Wen-Chao Song. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34-50. doi: 10.1038/cr.2009.139. (Pub online 15 December 2009).
  22. Medzhitov R, Janeway C .Jr. Innate immunity. N Engl J Med. 2000;343:338-44. doi: 10.1056/NEJM200008033430506
  23. Medzhitov R, Janeway C.A .Jr. Decoding the patterns of self and nonself by the innate immune system. Science. 2002;296:298-300. doi: 10.1126/science.1068883
  24. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell. 2002;111:927-30. doi: 10.1016/S0092-8674(02) 01201-1
  25. Epstein J, Eichbaum Q, Sheriff S, Ezekowitz R.A. The collectins in innate immunity. Curr Opin Immunol. 1996;8:29-35. doi: 10.1016/ S0952-7915(96)80101-4
  26. Fujita T, Endo Y, Nonaka M. Primitive complement system - recognition and activation. Mol Immunol. 2004;41:103-11. doi: 10.1016/ j.molimm.2004.03.026
  27. Harmat V, Gal P, Kardos J, et al. The structure of MBL-associated serine protease-2 reveals that identical substrate specificities of C1s and MASP-2 are realized through different sets of enzyme - substrate interactions. J Mol Biol. 2004;342:1533-46. doi: 10.1016/j.jmb.2004.07.014
  28. Bally I, Rossi V, Lunardi T, et al. Identification of the C1q - binding sites of human C1r and C1s: a refined three - dimensional model of the C1 complex of complement. J Biol Chem. 2009;284:19340-8. doi: 10.1074/ jbc.M109.004473
  29. Gal P, Barna L, Kocsis A, Zavodszky P. Serine proteases of the classical and lectin pathways: similarities and differences. Immunobiology. 2007;212:267-77. doi: 10.1016/j.imbio.2006.11.002
  30. Matsushita M, Endo Y, Fujita T. MASP1 (MBL-associated serine protease 1). Immunobiology. 1998;199:340-7. doi: 10.1016/S0171-2985(98)80038-7
  31. Dahl M.R, Thiel S, Matsushita M, et al. MASP-3 and its association with distinct complexes of the mannan - binding lectin complement activation pathway. Immunity. 2001;15:127-35. doi: 10.1016/S1074-7613(01)00161-3
  32. Takahashi M, Iwaki D, Kanno K, et al. Mannose - binding lectin (MBL)-associated serine protease (MASP)-1 contributes to activation of the lectin complement pathway. J Immunol. 2008;180:6132-8. doi: 10.4049/jimmunol.180.9.6132
  33. Dobo J, Harmat V, Beinrohr L, et al. MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity. J Immunol. 2009;183:1207-14. doi: 10.4049/jimmunol.0901141
  34. Hourcade D.E. Properdin and complement activation: a fresh perspective. Curr Drug Targets. 2008;9:158-64. doi: 10.2174/13894500 8783502458
  35. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272(34):20963-6. doi: 10.1074/ jbc.272.34.20963
  36. Bhakdi S, Dorweiler B, Kirchmann R, et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exper Med. 1995;182(6):1959-71. doi: 10.1084/jem.182.6.1959
  37. Torzewski M, Suriyaphol P, Paprotka K, et al. Enzymatic modification of low - density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. Arterioscler Thromb Vasc Biol. 2004;24(11):2130-6. doi: 10.1161/01.ATV.0000144016. 85221.66
  38. Steinberg D, Parthasarathy S, Carew T.E, Khoo J.C, Witztum J.L. Beyond cholesterol: modifications of low - density lipoprotein that increase its atherogenicity. New Engl J Med. 1989;320(14):915-24. doi: 10.1056/NEJM198904063201407
  39. Wieland E, Parthasarathy S, Steinberg D. Peroxidase - dependent metal - independent oxidation of low density lipoprotein in vitro: a model for in vivo oxidation? Proc Nat Acad Sci U S A. 1993;90(13):5929-33. doi: 10.1073/pnas.90.13.5929
  40. Chao F.F, Amende L.M, Blanchette-Mackie E.J, et al. Unesterified cholesterol - rich lipid particles in atherosclerotic lesions of human and rabbit aortas. Am J Pathol. 1988;131(1):73-83.
  41. Chao F.F, Blanchette-Mackie E.J, Tertov V.V, Skarlatos S.I, Chen Y.J, Kruth H.S. Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein to a liposome. J Biol Chem. 1992;267(7): 4992-8.
  42. Torzewski M, Lackner K.J. Initiation and progression of atherosclerosis - enzymatic or oxidative modification of low - density lipoprotein? Clin Chem Lab Med. 2006;44(12):1389-94. doi: 10.1515/CCLM.2006.259
  43. Seifert P.S, Hugo F, Tranum-Jensen J, Zahringer U, Muhly M, Bhakdi S. Isolation and characterization of a complement - activating lipid extracted from human atherosclerotic lesions. J Exper Med. 1990;172(2):547-57. doi: 10.1084/jem.172.2.547
  44. Gaboriaud C, Thielens N.M, Gregory L.A, Rossi V, Fontecilla-Camps J.C, Arlaud G.J. Structure and activation of the C1 complex of complement: unraveling the puzzle. Trends Immunol. 2004;25(7):368-73. doi: 10.1016/j.it.2004.04.008
  45. Arlaud G.J, Biro A, Wai Li Ling. Enzymatically Modified Low-Density Lipoprotein Is Recognized by C1q and Activates the Classical Complement Pathway. J Lipids. 2011;2011:Article ID 376092, 5 pages.
  46. Biró A, Thielens N.M, Cervenák L, Prohászka Z, Füst G, Arlaud G.J. Modified low density lipoproteins differentially bind and activate the C1 complex of complement. Mol Immunol. 2007;44(6):1169-77. doi: 10.1016/j.molimm.2006.06.013
  47. Biro A, Ling W.L, Arlaud G.J. Complement protein c1q recognizes enzymatically modified low - density lipoprotein through unesterified fatty acids generated by cholesterol esterase. Biochemistry. 2010;49 (10):2167-76. doi: 10.1021/bi9021022
  48. Ziccardi R.J. A new role for C1-inhibitor in homeostasis: control of activation of the first component of human complement. J Immunol. 1982;128(6):250-8.
  49. Garlatti V, Chouquet A, Lunardi T, et al. Cutting edge: C1q binds deoxyribose and heparan sulfate through neighboring sites of its recognition domain. J Immunol. 2010;185(2):808-12. doi: 10.4049/jimmunol.1000184
  50. Pentikäinen M.O, Lehtonen E.M.P, Kovanen P.T. Aggregation and fusion of modified low density lipoprotein. J Lipid Res. 1996;37(12): 2638-49.
  51. Oorni K, Pentikainen M.O, Ala-Korpela M, Kovanen P.T. Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J Lipid Res. 2000;41(11):1703-14.
  52. Kothari H.V, Bonner M.J, Miller B.F. Cholesterol ester hydrolase in homogenates and lysosomal fractions of human aorta. Biochim Biophys Acta. 1970;202(2):325-31. doi: 10.1016/0005-2760(70)90194-3
  53. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165-97. doi: 10.1146/annurev. immunol.021908.132620
  54. Mogilenko D.A, Kudriavtsev I.V, Trulioff A.S, Shavva V.S, Dizhe E.B, Missyul B.V, Zhakhov A.V, Ischenko A.M, Perevozchikov A.P, Orlov S.V. Modified Low Density Lipoprotein Stimulates Complement C3 Expression and Secretion via Liver X Receptor and Toll - like Receptor 4 Activation in Human Macrophages. J Biol Chem. 2012 Feb 17;287(8):5954-68. doi: 10.1074/jbc.M111.289322 [Pub online 2011 Dec 22].
  55. Hansson G.K, Libby P, Schönbeck U, Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281-91. doi: 10.1161/01.RES.0000029784.15893.10
  56. Calkin A.C, Tontonoz P. Liver X receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:1513-8. doi: 10.1161/ATVBAHA.109.191197
  57. Miller Y.I, Chang M.K, Binder C.J, Shaw P.X, Witztum J.L. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol. 2003;14:437-45. doi: 10.1097/00041433-200310000-00004
  58. Purwar R, Wittmann M, Zwirner J, Oppermann M, Kracht M, Dittrich-Breiholz O, Gutzmer R, Werfel T. Induction of C3 and CCL2 by C3a in keratinocytes. A novel autocrine amplification loop of inflammatory skin reactions. J Immunol. 2006;177:4444-50. doi: 10.4049/jimmunol.177.7.4444

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies